Bayer Canada Partners with Mint Pharmaceuticals to Enhance Access to ADALAT® XL 30 mg Tablets Across the Country
Bayer Canada has announced a significant new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL 30 mg tablets throughout Canada. The agreement, which came into effect on September 3, 2025, represents a strategic collaboration aimed at ensuring that patients and healthcare providers have reliable access to this trusted cardiovascular therapy.
Strengthening Access and Reliability in the Canadian Pharmaceutical Market
ADALAT® XL (nifedipine extended-release tablets) is a widely prescribed medication indicated for the management of chronic stable angina and mild to moderate essential hypertension. With cardiovascular diseases continuing to affect a large proportion of the Canadian population, ensuring consistent availability of medications such as ADALAT® XL is critical. Recognizing this, Bayer Canada sought a partner with a proven record in pharmaceutical distribution and supply chain management, leading to its collaboration with Mint Pharmaceuticals Inc.
“This partnership reflects our commitment to Canadian patients and healthcare professionals,” said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. “By collaborating with Mint Pharmaceuticals, we can leverage their extensive distribution network and operational expertise. Our goal is to make sure that ADALAT® XL remains readily accessible to patients who rely on it for the management of chronic angina and hypertension.”
Mint Pharmaceuticals: A Trusted Partner in Pharmaceutical Distribution
Mint Pharmaceuticals Inc., a Canadian-owned and operated company, has built a reputation over the past 15 years for reliability, high-quality service, and resilience in pharmaceutical supply. The company has consistently demonstrated its ability to maintain uninterrupted access to essential medicines across Canada, even during periods of high demand or supply chain disruptions.
“Canadian patients and healthcare providers depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint,” said Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals Inc. “Partnering with Bayer reinforces our shared commitment to reliability, quality, and patient care. Our best-in-class supply chain, built over the past 15 years, allows us to provide seamless access to ADALAT® XL, ensuring Canadians can obtain this trusted therapy without interruption.”
Mint Pharmaceuticals has become a cornerstone of the Canadian pharmaceutical industry, recognized for its proactive approach to supply chain management. Over the last decade, the company has addressed 23 national drug shortages involving 16 essential medicines, ensuring that patients across Canada continue to receive their prescribed therapies.
Enhancing Patient Access Through Strategic Collaboration
The collaboration between Bayer Canada and Mint Pharmaceuticals represents a holistic approach to patient care. Beyond simply distributing a medication, the partnership emphasizes the importance of timely availability, regulatory compliance, and adherence to the highest standards of quality management. By combining Bayer’s global expertise in pharmaceutical innovation with Mint’s robust Canadian distribution network, the collaboration aims to optimize patient outcomes and reinforce confidence in the supply of essential cardiovascular therapies.
ADALAT® XL is widely recognized for its effectiveness in managing chronic stable angina, a condition characterized by recurrent chest pain resulting from reduced blood flow to the heart. Additionally, its role in controlling mild to moderate essential hypertension—a key risk factor for heart disease, stroke, and other cardiovascular complications—makes it an essential component of the Canadian cardiovascular therapy landscape.
By ensuring continuous access to ADALAT® XL through this partnership, Bayer Canada and Mint Pharmaceuticals are addressing a critical need in the healthcare system: reliable availability of high-quality cardiovascular medications for patients across diverse geographic regions, including remote and underserved communities.
Commitment to Quality and Patient-Centric Service
Central to this partnership is a shared dedication to maintaining the highest quality standards. Both Bayer Canada and Mint Pharmaceuticals adhere to stringent regulatory and industry requirements to ensure that every tablet of ADALAT® XL distributed meets rigorous safety, efficacy, and quality benchmarks.
“Quality is at the heart of everything we do,” Friedrich emphasized. “Our patients and healthcare providers expect nothing less than excellence. This collaboration enables us to uphold that standard while expanding our reach across the Canadian healthcare landscape.”
The partnership also highlights the importance of transparency and accountability in pharmaceutical distribution. By providing timely updates, robust tracking systems, and responsive customer service, Mint Pharmaceuticals ensures that pharmacies, hospitals, and clinics have accurate information regarding product availability. This level of operational efficiency is essential to maintaining uninterrupted patient care and minimizing the risk of therapy gaps.
Mint Pharmaceuticals: Growth, Recognition, and Industry Leadership
Mint Pharmaceuticals has consistently demonstrated its capacity for growth and innovation in the Canadian pharmaceutical sector. In 2024, the company celebrated the launch of its 100th molecule in Canada, marking a major milestone in its portfolio expansion. This achievement underscores Mint’s commitment to providing high-quality, affordable medicines across a wide range of therapeutic areas.
The company’s leadership and operational excellence have been widely recognized. Mint has been named one of Canada’s Best Managed Companies by Deloitte for seven consecutive years, achieving Platinum Club status in 2025—a distinction reserved for organizations that demonstrate sustained excellence in business performance, strategic direction, and organizational capability. Furthermore, Mint is an active member of the Canadian Generic Pharmaceutical Association (CGPA), contributing to the advancement of industry standards and practices.
By partnering with Bayer, Mint Pharmaceuticals is extending its reach into innovative branded therapies, leveraging its distribution capabilities to enhance access to trusted medications such as ADALAT® XL. This collaboration not only strengthens the supply chain but also reaffirms Mint’s role as a critical partner in ensuring the availability of essential medicines in Canada.
Bayer: Global Leadership in Health and Life Sciences
Bayer is a global enterprise with a long-standing commitment to advancing healthcare and nutrition. With the mission of “Health for all, Hunger for none,” Bayer aims to improve lives and support sustainable development by addressing the major challenges associated with population growth and aging. The company’s products and services span a wide range of therapeutic areas, emphasizing innovation, quality, and patient-centric care.
In fiscal 2024, Bayer employed approximately 93,000 people worldwide and achieved sales of 46.6 billion euros, reflecting its global reach and influence in the life sciences sector. The company invested 6.2 billion euros in research and development, demonstrating its commitment to advancing medical innovation and delivering new treatment options to patients.
The Bayer brand is recognized worldwide for its reliability, trustworthiness, and high-quality products. Its presence in Canada reflects this global ethos, ensuring that Canadian patients have access to leading pharmaceutical therapies, including those addressing cardiovascular conditions. By collaborating with Mint Pharmaceuticals, Bayer Canada reinforces its dedication to enhancing healthcare outcomes and patient access within the country.
Looking Ahead: Ensuring Continuous Access and Patient Care
The new distribution partnership between Bayer Canada and Mint Pharmaceuticals is more than a business agreement; it represents a commitment to Canadian patients, healthcare providers, and the broader healthcare system. By leveraging each organization’s strengths—Bayer’s expertise in innovative therapies and Mint’s resilient, high-quality distribution infrastructure—the partnership is well-positioned to ensure uninterrupted access to ADALAT® XL across Canada.
This collaboration underscores the importance of strategic partnerships in addressing the challenges of modern healthcare, where timely access to essential medications can significantly impact patient outcomes. Both companies remain committed to ongoing evaluation and optimization of the supply chain, ensuring that ADALAT® XL is consistently available, regardless of market pressures or logistical challenges.
Conclusion
The partnership between Bayer Canada and Mint Pharmaceuticals Inc. represents a landmark step in the distribution of ADALAT® XL 30 mg tablets, ensuring that patients with chronic stable angina and mild to moderate essential hypertension have uninterrupted access to this vital therapy. Through shared values of quality, reliability, and patient-centric service, the two companies are setting a new standard for pharmaceutical distribution in Canada.
As Bayer continues to advance innovative healthcare solutions and Mint Pharmaceuticals strengthens its distribution capabilities, Canadian patients and healthcare providers can look forward to a future where trusted medications are consistently available, safe, and delivered with the highest standards of quality. This partnership exemplifies the importance of collaboration, innovation, and operational excellence in modern healthcare, reinforcing the commitment of both companies to improving patient outcomes and supporting the health of communities across Canada.
About Mint Pharmaceuticals Inc.
Mint Pharmaceuticals is a leading Canadian-owned and operated manufacturer of high-quality, affordable generic medicines. Known for its resilient and robust supply chain, Mint has successfully mitigated 23 national drug shortages across 16 essential medicines in the past decade. With a focus on quality, reliability, and patient-centric service, Mint continues to expand its portfolio and contribute to the Canadian healthcare system.
Bayer is a global life sciences company with core competencies in healthcare and nutrition. With a mission to advance health for all and address major societal challenges, Bayer develops innovative products and services to support patients and communities worldwide. The company is dedicated to sustainability, research-driven growth, and delivering high-quality, reliable products. For more information, visit www.bayer.ca.
